

## Heme SPOREs Investigators Meeting Invitation Email

Dear SPORE Directors in Hematologic Malignancies,

With great pleasure we invite you to the Hematologic SPORE Investigators Meeting. The meeting is organized by the Translational Research Program at NCI together with an appointed Steering Committee consisted of representatives from SPOREs in Leukemia, Lymphoma, and Myeloma. The meeting will assemble investigators from Heme SPOREs and hematologic projects in thematic SPOREs. The NCI program staff and SPORE patient advocates with interest in hematologic malignancies will be invited as observers. We hope this venue will offer many new collaborative opportunities within the Heme SPORE community.

The meeting will advance the state-of -the science to address the following four critical areas: (i) Molecular Diagnostics, (ii) Targeted Therapies, (iii) Immunotherapy, and (iv) Technology Development through facilitated breakout sessions. The breakout sessions will endeavor to develop collaborative approaches to address key questions in the field and define promising scientific areas.

The meeting will be held virtually and will be hosted by the University of Iowa College of Medicine, Holden Comprehensive Cancer Center.

Please register for the meeting by September 10, 2021 on the meeting website. Registration questions should be directed to Mia Garrett ([mia.garrett@nih.gov](mailto:mia.garrett@nih.gov)) or 240-276-6031.

Thank you and best regards,

Igor Kuzmin, PhD  
National Cancer Institute, DCTD, TRP

### **Abstract Submission Instructions**

Investigators from 10 current Heme SPOREs will present data and discuss opportunities for collaborations. Each Hematology-associated SPORE is expected to contribute one overview presentation reflecting on the entire scope of the program. Up to two additional abstracts can be submitted. The two presentations will be focused on the SPORE components with the highest collaborative potential in one of the four critical areas:

- Molecular Diagnostics
- Targeted Therapies
- Immunotherapy
- Technology Development

Abstract size is limited to 350 word maximum. Images and hyperlinks are allowed.

All abstracts will be collated into a publicly published abstract book that will eventually be hosted on the TRP website ([trp.cancer.gov](http://trp.cancer.gov)).

Please submit the abstract here using MS Word (avoid .pdf). The file should follow this nomenclature: SPORE Director last name, file name (Overview, etc.).

Abstract submission questions can be addressed to Mia Garrett ([mia.garrett.garrett@nih.gov](mailto:mia.garrett.garrett@nih.gov)) or 240-276-6031. Scientific questions should be directed to Igor Kuzmin ([igor.kuzmin@nih.gov](mailto:igor.kuzmin@nih.gov)) or 240-276-5684.